GlaxoSmithKline: Lupus Erythematosus, Systemic trials

The registry lists 43 Lupus Erythematosus, Systemic studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 27 have results posted.

Phase 1 14Phase 2 7Phase 3 10Phase 4 5No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)RecruitingNCT07371468Phase 1
• A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus ErythematosusCompletedNCT05917288Phase 1Results posted
• Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus NephritisCompletedNCT04971590Results posted
• Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)CompletedNCT04908865Phase 4Results posted
• Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT04179032Phase 2Results posted
• Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy SubjectsCompletedNCT04136145Phase 1Results posted
• BENLYSTA® Special Drug Use InvestigationCompletedNCT03370263Results posted
• A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVECompletedNCT03312907Phase 3Results posted
• Belimumab Phase I Study in Chinese Subjects With Systemic Lupus ErythematosusCompletedNCT02880852Phase 1Results posted
• A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an AutoinjectorCompletedNCT02124798Phase 2Results posted
• Belimumab Treatment Holiday and Treatment Re-start Study in Lupus PatientsCompletedNCT02119156Phase 3Results posted
• Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) RegistryCompletedNCT01729455Results posted
• Belimumab Assessment of Safety in SLECompletedNCT01705977Phase 4Results posted
• Pediatric Lupus Trial of Belimumab Plus Background Standard TherapyCompletedNCT01649765Phase 2Results posted
• Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompletedNCT01639339Phase 3Results posted
• Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)CompletedNCT01632241Phase 4Results posted
• BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115CompletedNCT01597622Phase 3Results posted
• A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01597492Phase 4Results posted
• Study of Belimumab Administered Subcutaneously to Healthy SubjectsCompletedNCT01583530Phase 1Results posted
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01484496Phase 3Results posted
• GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast AsiaCompletedNCT01345253Phase 3Results posted
• Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)TerminatedNCT00732940Phase 2Results posted
• A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United StatesCompletedNCT00724867Phase 3Results posted
• A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057CompletedNCT00712933Phase 3Results posted
• A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02CompletedNCT00583362Phase 2Results posted
• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00424476Phase 3Results posted
• A Study of Belimumab in Subjects With Systemic Lupus ErythematosusCompletedNCT00410384Phase 3Results posted
• Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00071487Phase 2Results posted
• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsActive, not recruitingNCT06576271Phase 1
• A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune DiseaseWithdrawnNCT06413511Phase 1
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT06411249Phase 4
• A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy ParticipantsSuspendedNCT06188507Phase 1
• Compassionate Use for Subcutaneous (SC) BelimumabNo longer availableNCT03125486
• A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184CompletedNCT01953835Phase 1
• Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76CompletedNCT01914770
• A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy SubjectsCompletedNCT01894360Phase 1
• An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184TerminatedNCT01777256Phase 2
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and GenderCompletedNCT01687309Phase 1
• WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)CompletedNCT01616472
• Belimumab (BENLYSTA®) Pregnancy RegistryCompletedNCT01532310
• Japanese phase1 Study of Belimumab (IV vs SC)CompletedNCT01516450Phase 1
• Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01381536Phase 1
• Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00657007Phase 1